Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$77.46M+608.73%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dominick C. Colangelo
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 398
- Beta
- 1.05
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 9.23
Financials
Revenue
$77.46M+608.7%Net Income
$2.21MEBITDA
$5.62MFree Cash Flow
$14.26MEPS (diluted)
$0.04Shares Outstanding (diluted)
50.92M+123.9%Operating Expenses
$55.97MCash & Debt
$162.46MRevenue by Segment (annual)
$239.51MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $276.26M | $16.52M | $0.33 |
| 2024 | $237.22M | $10.36M | $0.21 |
| 2023 | $197.52M | $-3.18M | $-0.07 |
| 2022 | $164.37M | $-16.71M | $-0.35 |
| 2021 | $156.18M | $-7.47M | $-0.16 |
| 2020 | $124.18M | $2.86M | $0.06 |
| 2019 | $117.85M | $-9.66M | $-0.18 |
| 2018 | $90.86M | $-8.14M | $-0.20 |
| 2017 | $63.92M | $-17.29M | $-0.52 |
| 2016 | $54.38M | $-19.57M | $-0.85 |
| 2015 | $51.17M | $-16.34M | $-0.69 |
| 2014 | $28.80M | $-19.92M | $-1.71 |
| 2013 | $19.0K | $-15.62M | $-5.18 |
| 2012 | $21.0K | $-29.47M | $-14.31 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.48
- Implied price
- $8.64
- Return from $39.60
- -26.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $4.29 — -89.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -38.3% | -35.5% | -33.1% | -31.0% | -29.1% |
| 3.0% | -35.1% | -32.2% | -29.7% | -27.5% | -25.5% |
| 8.0% | -32.0% | -28.9% | -26.3% | -23.9% | -21.9% |
| 13.0% | -28.9% | -25.6% | -22.8% | -20.4% | -18.3% |
| 18.0% | -25.7% | -22.3% | -19.4% | -16.9% | -14.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (2)
- Newsseekingalpha.com·6h ago·Positive
Vericel: MACI And Regenerative Knee Cartilage Vericel's MACI already has an established commercial base, which I think gives them an easier path for future growth. MACI's arthroscopic delivery could also help it expand among surgeons. That's why VCEL's Burlington added capacity is timely if demand indeed increases. I also like that VCEL's recently gained BARDA contract helps with its Burn Care business. VCEL also has a potential UK launch and an ankle indication in the works.
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026 BURLINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15th, 2026.
View source ↗
Earnings
Thu, Nov 5(in 7 weeks)
Consensus estimate $0.02 per share
Typical surprise +22.6% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.04 vs $-0.03beat
- Thu, May 7$-0.12 vs $-0.15beat
- Thu, Feb 26$0.45 vs $0.45beat
- Thu, Nov 6$0.10 vs $-0.02beat
- Thu, Jul 31$-0.01 vs $-0.04beat
- Thu, May 8$-0.23 vs $-0.09miss
Estimates and results for VCEL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VCEL officers and directors.
- Bought
- —
- Sold
- $5.9m
0 trades
22 trades
- Mclaughlin Kevin Fsold
- Halpin Michaelsold
- Siegal Jonathansold
- Siegal Jonathansold
- Mara Joseph Anthony Jrsold
- Hopper Jonathan Marksold
- Flynn Sean C.sold
- Halpin Michaelsold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in VCEL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.